Maternal and perinatal factors related to maternal-infant transmission of HIV-1 in the P2C2 HIV study: The role of EBV shedding

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 19, Issue 5, 1998, Pages 462-470

  Pitt, Jane ^a   Schluchter, Mark ^b   Jenson, Hal ^c   Kovacs, Andrea ^d   LaRussa, Philip ^a   McIntosh, Kenneth ^e   Boyer, Pamela ^f   Cooper, Ellen ^g   Goldfarb, Johanna ^b   Hammill, Hunter ^h   Hodes, David ⁱ   Peavy, Hannah ^j   Sperling, Rhoda ⁱ   Tuomala, Ruth ^k   Shearer, William ^l  

^a Columbia Univ Coll Phys Surgs ^*  (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d LAC USC MEDICAL CENTER   (United States)

^e BOSTON MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l TEXAS CHILDREN S HOSPITAL   (United States)

more..

Author keywords

Duration of ruptured membranes; EBV and CMV infection; HIV 1 maternal infant transmission

Indexed keywords

ZIDOVUDINE;

ADULT; ARTICLE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PLACENTAL TRANSFER; PREDICTION; PREMATURE FETUS MEMBRANE RUPTURE; PRIORITY JOURNAL; RISK FACTOR; SEROCONVERSION; VERTICAL TRANSMISSION; VIRUS SHEDDING; VIRUS TRANSMISSION;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0032535465     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199812150-00004     Document Type: Article

References (28)

1. Conner EM, Sperling RS, Gelber R, et al. for the ACTG Protocol 076 Study. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
2. Simpson JB, Shapiro ED, Andiman WA. Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:145-52.
3. 2 HIV Study Group. The pediatric pulmonary and cardiovascular complications of vertically transmitted HIV infection study: design and methods. J Clin Epidemiol 1996;49:1285-94.
4. Sheon AR, Fox He, Rich KC, et al. The Women and Infants Transmission Study (WITS) of maternal-infant hiv transmission: study design, methods, and baseline data. J Womens Health 1996; 4:69-78.
5. Calvelli T, Denny TN, Paxton H, Gelman R, Kagan J. Guidelines for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry 1993;14:702-15.
6. Demmler GJ. Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis 1991;13:8-10.
7. Chang RS, Lewis JP, Abildgaard CF. Prevalence of oropharyngeal excreters of leukocyte-transforming agents among a human population. N Engl J Med 1973;289:1325-9.
8. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938;27:493-7.
9. Jenson HB, Ench Y, Sumaya CV. Epstein-Barr virus. In Rose NR, de Macario EC, Folds H, Lane HC, Nakamura RM, eds. Manual of clinical laboratory immunology, 5th ed. Washington, DC: American Society for Microbiology Press, 1997:634-43.
10. Hollinger FB, Bremer JW, Myers LE, Gold JWM, McQuay L. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J Clin Microbiol 1992;30:1787-94.
11. Armitage P. Tests for linear trend in proportions and frequencies. Biometrics 1955;11:375-86.
12. Kenney S, Kamine J, Markovitz D, Fenrick R, Pagano J. An Epstein-Barr virus immediate-early gene product trans-activates gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci USA 1988;85:1652-6.
13. Zhang RD, Henderson EE. CD4 mRNA expression in CD19 positive B cells and its suppression by the Epstein-Barr virus. Virology 1994;198:709-13.
14. Guan M, Zhang RD, Wu B, Henderson EE. Infection of primary CD4 and CD8 lymphocytes by Epstein Barr virus enhances human immunodeficiency virus expression. J Virol 1996;70:7341-6.
15. Poulin L, Paquette N, Mori S, Lapointe, Darveau A. Productive infection of normal CD40 activated human B lymphocytes by HIV-1. AIDS 1994;8:1539-44.
16. Zhang RD, Guan M, Park Y, et al. Synergy between human immunodeficiency virus type 1 and Epstein-Barr virus in T lympho-blastoid cell lines. AIDS Res Hum Retroviruses 1997;13:161-71.
17. Guan M, Zhang RD, Wu B, Henderson EE. Infection of primary CD4 and CDS lymphocytes by Epstein Barr virus enhances human immunodeficiency virus expression. J Virol 1996;70:7341-6.
18. Bourgault I, Gomez A, Gomard E, Levy JP. Limiting dilution analysis of the HLA restriction of anti-Epstein-Barr virus specific cytolytic T lymphocytes. Clin Exp Immunol 1991;84:501-7.
19. Blumberg RS, Parxadis T, Byington R, Henle W, Hirsch MS, Schooley RT. Effects of human immunodeficiency virus on the cellular immune response to Epstein-Barr virus in homosexual men: characterization of the cytotoxic response and lymphokine production. J Infect Dis 1987;155:877-90.
20. Lucht E, Biberfeld P, Linde A. Epstein-Barr virus (EBV) DNA in saliva and EBV serology of HIV-1-infected persons with and without hairy leukoplakia. J Infect 1995;31:189-94.
21. Rahman MA, Kingsley LA, Breinig MK, et al. Enhanced antibody responses to Epstein-Barr virus in HIV-intected homosexual men. J Infect Dis 1989;159:472-9.
22. Margalith M, Sarov B, Sarov I, et al. Serum IgG and IgA antibodies specific to Epstein-Barr virus capsid antigen in a longitudinal study of human immunodeficiency virus infection and disease progression in homosexual men. AIDS Res Hum Retroviruses 1990; 6:607-16.
23. 2 HIV Study Group. Incidence of premature birth and neonatal respiratory disease in infants of HIV positive mothers. J Pediatr 1997;131:851-6.
24. St Louis E, Kamenga M, Brown C, et al. Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic and placental factors. JAMA 1993;269:2853-9.
25. Pitt J, Brambilla D, Reichelderfer D, et al. Maternal immunologic and virologic risk factors for infant HIV type 1 infection: findings from the Women and Infants Transmission Study. J Infect Dis 1997;175:567-75.
26. Cooper ER, Nugent RP, Diaz C, et al. After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis 1996;174:1207-11.
27. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA 1996;275:1514-15.
28. Landesman SH, Kalish LA, Burns DN, et al. for the WITS Transmission Study. Obstetrical factors and the transmission of human immunodeficiency virus Type 1 from mother to child. N Engl J Med 1996;334:1617-23.